

REMARKS

The amendments to the claims are being made to make clear that the antigenic molecule recited in the claims is not covalently attached to the HBsAg particle.


Attached hereto is a copy of the Kedar et al., J. Immunother. 16:47-59 (1994) reference discussed on page 11 of the Amendment filed February 13, 2002. The temperature stability of IL-2 is shown in Table 1 under "heating".

Favorable consideration is respectfully requested.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By



Allen C. Yun
Registration No. 37,971

ACY:pr

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

F:\C\cohn\Reimann1\Pto\supplemental amendment.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 1 and 31 have been amended as follows:

1(Twice-amended). A method of stimulating or modulating a CTL response to an antigenic molecule in a mammalian subject, comprising administering to said subject an effective amount of a composition comprising an antigenic molecule either entrapped within the interior of an HBsAg particle or exposed or present at the surface of an HBsAg particle, wherein said antigenic molecule is not covalently attached to said HBsAg particle.

31(Once-amended). In a method of stimulating or modulating a CTL response to an antigenic molecule in a mammalian subject comprising administering an effective amount of a composition which comprises an antigenic molecule, an improvement wherein said antigenic molecule is either entrapped within the interior of an HBsAg particle or exposed or present at the surface of an HBsAg particle, said antigenic molecule being ~~a naturally occurring antigenic molecule or an antigenic fragment thereof which is~~ not covalently attached to said HBsAg particle modified.